Divis Laboratories Limited (NSE: DIVISLAB) and Sai Life Sciences Limited (NSE: SAILIFE) are both listed in the Pharmaceutical CDMO and CRO Services industry. Divis Laboratories has a market capitalisation of ₹2,64,022 Cr and Sai Life Sciences ₹32,761 Cr, as of 9 Nov 2026. Their P/E ratios are 102.8 and 93.9 respectively. Return on equity is 16.19% for Divis Laboratories and 15.13% for Sai Life Sciences. Over one year, Divis Laboratories's share price is up 70.0% and Sai Life Sciences's is up 99.0%.
| Metric | Divis Laboratories | Sai Life Sciences |
|---|---|---|
| NSE Symbol | DIVISLAB | SAILIFE |
| BSE Code | 532488 | 544306 |
| Share Price | ₹11,565.50 | ₹1,836.00 |
| Market Cap | ₹2,64,022 Cr | ₹32,761 Cr |
| P/E Ratio | 102.8 | 93.9 |
| Return on Equity | 16.19% | 15.13% |
| Return on Assets | 10.07% | 8.57% |
| Dividend Yield | 0.30% | — |
| Beta (1Y) | 0.28 | 0.4 |
| 1-Year Price Change | +70.0% | +99.0% |
| 3-Month Price Change | +39.3% | +28.7% |
| 52-Week Range | ₹5,647.50 – ₹11,824.00 | ₹783.85 – ₹1,897.30 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹3,676 Cr | ₹659 Cr |
| Quarterly Net Profit | ₹1,127 Cr | ₹98 Cr |
| Net Margin | 30.7% | 14.9% |
| EPS (Basic, Quarter) | ₹42.49 | ₹4.63 |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | Hyderabad, Telangana |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Re…
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
Divis Laboratories has a market capitalisation of ₹2,64,022 Cr, against ₹32,761 Cr for Sai Life Sciences as of 9 Nov 2026, about 8.1 times the size by market cap.
Divis Laboratories has a P/E of 102.8 and Sai Life Sciences a P/E of 93.9 as of 9 Nov 2026.
Divis Laboratories has a return on equity of 16.19% and Sai Life Sciences 15.13%.
Divis Laboratories's share price is up 70.0% over one year and Sai Life Sciences's is up 99.0%.
Divis Laboratories reported revenue of ₹3,676 Cr and net profit of ₹1,127 Cr for Q2 FY27. Sai Life Sciences reported revenue of ₹659 Cr and net profit of ₹98 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.